These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10826865

  • 1. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits.
    Lipsky MS, Waters T, Sharp LK.
    J Am Board Fam Pract; 2000; 13(3):178-82. PubMed ID: 10826865
    [Abstract] [Full Text] [Related]

  • 2. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
    Gurwitz JH, McLaughlin TJ, Fish LS.
    Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
    [Abstract] [Full Text] [Related]

  • 3. Trends in prescribing for vulvovaginal candidiasis in the United States.
    McCaig LF, McNeil MM.
    Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):113-20. PubMed ID: 15386715
    [Abstract] [Full Text] [Related]

  • 4. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
    Andrade SE, Gurwitz JH, Fish LS.
    Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
    [Abstract] [Full Text] [Related]

  • 5. The use of over-the-counter antifungal vaginitis preparations by college students.
    Lipsky MS, Taylor C.
    Fam Med; 1996 Apr; 28(7):493-5. PubMed ID: 8818620
    [Abstract] [Full Text] [Related]

  • 6. Improving appropriate use of antifungal medications: the role of an over-the-counter vaginal pH self-test device.
    Roy S, Caillouette JC, Faden JS, Roy T, Ramos DE.
    Infect Dis Obstet Gynecol; 2003 Apr; 11(4):209-16. PubMed ID: 15108867
    [Abstract] [Full Text] [Related]

  • 7. American Pharmaceutical Association review of literature on prescription to over-the-counter drug switches.
    Schulke DG.
    Clin Ther; 1998 Apr; 20 Suppl C():C124-33. PubMed ID: 9915099
    [Abstract] [Full Text] [Related]

  • 8. Physicians' perceptions of the impact of the reclassification of vaginal antifungal agents.
    Taylor CA, Lipsky MS.
    J Fam Pract; 1994 Feb; 38(2):157-60. PubMed ID: 8308507
    [Abstract] [Full Text] [Related]

  • 9. Vaginitis: making sense of over-the-counter treatment options.
    Angotti LB, Lambert LC, Soper DE.
    Infect Dis Obstet Gynecol; 2007 Feb; 2007():97424. PubMed ID: 18253469
    [Abstract] [Full Text] [Related]

  • 10. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: I. Analyses of a unique database.
    Mårdh PA, Wågström J, Landgren M, Holmén J.
    Infect Dis Obstet Gynecol; 2004 Jun; 12(2):91-7. PubMed ID: 15739823
    [Abstract] [Full Text] [Related]

  • 11. The "prescription-to-OTC switch" movement. Its effects on antifungal vaginitis preparations.
    Lipsky MS, Waters T.
    Arch Fam Med; 1999 Jun; 8(4):297-300. PubMed ID: 10418534
    [Abstract] [Full Text] [Related]

  • 12. Women's use of over-the-counter antifungal medications for gynecologic symptoms.
    Ferris DG, Dekle C, Litaker MS.
    J Fam Pract; 1996 Jun; 42(6):595-600. PubMed ID: 8656170
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Usage of antifungal drugs for therapy of genital Candida infections, purchased as over-the-counter products or by prescription: 2. Factors that may have influenced the marked changes in sales volumes during the 1990s.
    Mårdh PA, Wågström J, Landgren M, Holmén J.
    Infect Dis Obstet Gynecol; 2004 Jun; 12(2):99-108. PubMed ID: 15739824
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis.
    Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS.
    Obstet Gynecol; 2002 Mar; 99(3):419-25. PubMed ID: 11864668
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis.
    Fong IW.
    Pharmacoeconomics; 1996 Jun; 9(6):497-505. PubMed ID: 10160477
    [Abstract] [Full Text] [Related]

  • 19. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W, Brasch J, Cornely OA, Effendy I, Friese K, Ginter-Hanselmayer G, Hof H, Mayser P, Mylonas I, Ruhnke M, Schaller M, Weissenbacher ER.
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [Abstract] [Full Text] [Related]

  • 20. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
    Kalish SC, Bohn RL, Avorn J.
    Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.